Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/YieldMax MRNA Option Income Strategy ETF rated Sell due to high risk and overvalued optimism.
MRNA
$68.28
+$0.84 +1.25%

YieldMax MRNA Option Income Strategy ETF rated Sell due to high risk and overvalued optimism.

Market News
08 Apr 2026
Seeking Alpha
View Source
Bearish
pluang ai news

The YieldMax MRNA Option Income Strategy ETF (MRNY) is rated as a Sell because of significant downside risks and overly optimistic expectations about Moderna's drug pipeline. While MRNY's aggressive covered call strategy captures some upside, it provides limited protection against losses and yields lower income in flat markets. Moderna's revenue is structurally declining, and the market has already priced in progress from its oncology pipeline, making the ETF's valuation vulnerable. Both short- and long-term investors face unattractive risk-reward profiles as MRNY's net asset value and payouts could drop if Moderna's shares correct.

More News (MRNA)

Moderna's Q2 report expected uneventful; key focus on COVID vaccine demand and Phase III melanoma data.

Moderna's Q2 report expected uneventful; key focus on COVID vaccine demand and Phase III melanoma data.

Moderna is set to report its Q2 results on July 31, with expectations of a modest revenue decline due to seasonal COVID-19 vaccine demand. Jefferies forecasts a loss of $1.99 per share on about $100 million revenue, down from Q1's $389 million. Inves...

Company Fundamentals
Neutral
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App